Internal Medicine Doctors in Bluefield, VA Accepting Medicare

7 Internal Medicine doctors found. Showing 1 - 7

Dr. Naeem A Qazi, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 15 Westwood Medical Park, Bluefield, VA 24605 Phone: 276-326-1136    Fax: 276-326-1137

Mohammad Javed Rana, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2003 Leatherwood Ln, Bluefield, VA 24605 Phone: 276-322-0000    Fax: 276-322-0003

Dr. Oscar Fernando Figueroa, M.D. Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 103 Westwood Cmn, Bluefield, VA 24605 Phone: 276-322-3947    Fax: 276-322-2344

Dr. Jack Charles Meshel, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 10 Westwood Medical Park, Bluefield, VA 24605 Phone: 276-326-1995    Fax: 276-326-1996

Ashutosh Chandel, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 100 Westwood Commons, Bluefield, VA 24605 Phone: 276-326-1915    Fax: 276-326-1917

Dr. Jonathan R Hall, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 725 S College Ave, Bluefield, VA 24605 Phone: 276-326-3376

Kimberly Ann Matzel, PAC Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2111 College Ave, Bluefield Internal Medicine, Bluefield, VA 24605 Phone: 276-322-4661    Fax: 276-322-4663

News Archive

Mylan announces launch of Linezolid Tablets, 600 mg in U.S.

Mylan N.V. today announced the U.S. launch of Linezolid Tablets, 600 mg, which is the generic version of Pfizer's Zyvox Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product, which is indicated in adults and children for the treatment of certain infections caused by susceptible Gram-positive bacteria.

GSK and XenoPort resubmit NDA for Solzira in restless legs syndrome

GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira(TM) (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

CT imaging and serum LDH can predict survival in patients with metastatic melanoma

Combining CT imaging findings with baseline serum lactate dehydrogenase levels is showing promise as a way to predict survival in patients with metastatic melanoma being treated with anti-angiogenic therapy.

Women who exercised during teen years less likely to die from cancer in later life

Women who exercised during their teen years were less likely to die from cancer and all other causes during middle-age and later in life, according to a new study by investigators at Vanderbilt University Medical Center and the Shanghai Cancer Institute in China.

Read more Medical News

› Verified 5 days ago